Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
|Slideshows|June 29, 2017
Psychiatric Questions, Queries, and Quarrels
In psychiatry, hot debates abound if you just look around-and if this Special Report collection is any indication, the result is a balance of opinion and civility made richer by virtue of opposing views.
Advertisement
Advertisement
Related to this article
How VA clinicians treat veterans’ PTSD while managing suicide risk, using shared decisions, safety planning, and phase-based trauma therapies.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.
FDA clears Simtriyo, first NDSRI stimulant for ADHD ages 6 and older, as millions return to school—see what this means for treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Treating PTSD Among Veterans at Risk for Suicide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
Podcast: Not Always Panic. A Cardiologist and Psychiatrist on Reading a Racing Heart
4
Exploring a Misuse of Neuroscience: How Biology Has Been Used to Remove Responsibility in Youth
5